Has Michael Early received payments from drug or device companies?

Yes. Drug and device makers reported $4,148 in general payments to Michael Early across 147 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Early did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Early come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Early

Family Medicine · Fort Valley, GANPI 1376613570

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,409 and has fallen 94.8% since, to $125 in 2023.

$4,148in general payments, 2019–2025

Across 147 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$917
Pfizer$544
Novo Nordisk$449
Boehringer Ingelheim$393
Johnson & Johnson$294
Sanofi-aventis U.S. LLC$292
plus $1K from 12 others

What the payments were for

Food & beverage$4,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	37	$917
Pfizer	15	$544
Novo Nordisk	13	$449
Boehringer Ingelheim	10	$393
Johnson & Johnson	15	$294
Sanofi-aventis U.S. LLC	8	$292
AstraZeneca	7	$217
Amarin Pharma, Inc.	4	$170
Astellas Pharma US Inc	12	$164
Arbor Pharmaceuticals, Inc.	11	$157
Amgen(2 entities)	2	$144
Melinta Therapeutics, LLC	1	$124
Medtronic	1	$103
Lilly USA, LLC	6	$97
Merck	2	$34
Biogen	1	$20
Phadia US Inc.	1	$17
Medline Industries LP	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,148 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia →

Other family medicine in Fort Valley

Jeffrey KingsleyColumbus$404K
Debbie HaginsSavannah$279K
Yolanda WadeTyrone$233K
Julian HutchinsWarrenton$222K
Nadine Halliburton-FosterCumming$219K
Contessa MetcalfeAtlanta$157K
Elmore AlexanderStone Mountain$155K
Bantwal BaligaColumbus$115K
Avril CampbellFort Benning$108K
Mitzi RubinMarietta$103K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →